Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

Ampliphi Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel antibacterial therapies designed to address drug‐resistant infections. The company leverages phage‐derived lysins and small‐molecule antibiotics to create targeted treatments that rapidly kill pathogens while minimizing resistance development.

Its lead product candidate, exebacase, is a first‐in‐class lysin enzyme in Phase 3 trials for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) bloodstream infections, and its pipeline includes CF-370 for Gram‐negative infections and other lysin derivatives in preclinical stages. Ampliphi’s technology platform enables rapid engineering of enzymes to target a broad spectrum of bacterial pathogens, including those resistant to conventional antibiotics.

The company has established collaborations and licensing agreements to advance its pipeline and expand its commercial reach, partnering with academic institutions and biopharmaceutical companies. Ampliphi’s integrated development strategy combines proprietary R&D with external expertise to accelerate the translation of novel antimicrobial agents from lab to clinic.

Headquartered in Richmond, Virginia, Ampliphi Biosciences is dedicated to combating the global public health threat of antibiotic resistance by delivering innovative therapies that fill critical gaps in current treatment options. The company aims to build a diversified portfolio of antibacterial products to meet urgent medical needs worldwide.

Key Stats

• Today's Range: $1.85 to $1.98
• 50-Day Range: $1.23 to $2.03
• 52-Week Range: $0.15 to $1.37
• Volume: 9,774 shs
• Average Volume: 842,200 shs
• Market Capitalization: $63.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APHB Stock Analysis - Frequently Asked Questions

How have APHB shares performed this year?

Ampliphi Biosciences' stock was trading at $1.9490 at the start of the year. Since then, APHB stock has decreased by 3.0% and is now trading at $1.89.
View the best growth stocks for 2025 here.

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) released its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.07.

How do I buy shares of Ampliphi Biosciences?

Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ampliphi Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Protalix BioTherapeutics (PLX), Athersys (ATHX) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 3/25/2019
• Today: 7/02/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $63.26 million
• Optionable: Not Optionable
• Beta: N/A